Semaglutide briefing
What is Semaglutide?
Semaglutide is a modified molecule our bodies make, GLP1. It’s a protein made in the intestine and results in a decrease in blood sugars and appetite. A small change in the molecule allows the drug to last weeks in our bodies rather than minutes.
Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlutide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.
Semaglutide (USAN; trade name Ozempi c) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozemp ic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat.
Benefits of Semaglutide:
Slows down how quickly food leaves your stomach, leaving you with a feeling of fullness and satisfaction with smaller meals.
-Lowers blood sugars, in part by reducing the production of sugar in the liver.
-Slows Intestinal motility (movement of food from mouth out of the body).
-Stimulates insulin secretion by the pancreas.
FOR RESEARCH USE ONLY
Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The higher-dose formulation of semaglutide is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity (initial body mass index (BMI) ≥ 30 kg/m2) or who are overweight (initial BMI ≥ 27 kg/m2) and have at least one weight-related comorbidity.
A review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery.
There is evidence, primarily from animal studies, that semaglutide also reduces non-food cravings, such as for alcohol.
How to process the order?
- send us an email toinfo@bulkrawspharma.com with the following details: product names, quantity and your special requests (eg. need custom produced)
- we quote and confirm your request details
- we ship your order after payment done and offer tracking code & packing pictures within 1-3 days
- we will keep you updated of your order status
- order received and review our services
Payment terms
MoneyGram, Western Union, Bitcoin,T/T Bank transfer,USDT.escrow alibaba (credit card,paypal),etc.
Reviews
There are no reviews yet.